This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies.
|Trial Phase||Phase 1/2|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
The following laboratory values obtained ≤ 14 days prior to initiation of therapy:
Measurable disease of MM as defined by at least ONE of the following:
Cardiac Troponin T (cTnT) or I(cTnI)≥2×institutional ULN.